209 related articles for article (PubMed ID: 19464324)
41. Behavioural effects of chronic haloperidol and risperidone treatment in rats.
Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I
Behav Brain Res; 2006 Aug; 171(2):286-94. PubMed ID: 16697060
[TBL] [Abstract][Full Text] [Related]
42. Optimizing atypical antipsychotic treatment strategies in the elderly.
Katz IR
J Am Geriatr Soc; 2004 Dec; 52(12 Suppl):S272-7. PubMed ID: 15541168
[No Abstract] [Full Text] [Related]
43. FDA warns antipsychotic drugs may be risky for elderly.
Kuehn BM
JAMA; 2005 May; 293(20):2462. PubMed ID: 15914734
[No Abstract] [Full Text] [Related]
44. A model of anticholinergic activity of atypical antipsychotic medications.
Chew ML; Mulsant BH; Pollock BG; Lehman ME; Greenspan A; Kirshner MA; Bies RR; Kapur S; Gharabawi G
Schizophr Res; 2006 Dec; 88(1-3):63-72. PubMed ID: 16928430
[TBL] [Abstract][Full Text] [Related]
45. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
46. Atypical antipsychotics and dopamine D(1) receptor agonism: an in vivo experimental study using core temperature measurements in the rat.
Oerther S; Ahlenius S
J Pharmacol Exp Ther; 2000 Feb; 292(2):731-6. PubMed ID: 10640312
[TBL] [Abstract][Full Text] [Related]
47. alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs.
Kalkman HO; Loetscher E
Eur J Pharmacol; 2003 Feb; 462(1-3):33-40. PubMed ID: 12591093
[TBL] [Abstract][Full Text] [Related]
48. [Psychotropics and weight gain].
Sahli Ch; Bryois Ch
Praxis (Bern 1994); 2004 Aug; 93(35):1393-401. PubMed ID: 15468580
[TBL] [Abstract][Full Text] [Related]
49. Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation.
Cosi C; Waget A; Rollet K; Tesori V; Newman-Tancredi A
Brain Res; 2005 May; 1043(1-2):32-41. PubMed ID: 15862515
[TBL] [Abstract][Full Text] [Related]
50. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
51. Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties.
Rauly-Lestienne I; Boutet-Robinet E; Ailhaud MC; Newman-Tancredi A; Cussac D
Naunyn Schmiedebergs Arch Pharmacol; 2007 Oct; 376(1-2):93-105. PubMed ID: 17786406
[TBL] [Abstract][Full Text] [Related]
52. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
53. Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour.
Dahan L; Husum H; Mnie-Filali O; Arnt J; Hertel P; Haddjeri N
J Psychopharmacol; 2009 Mar; 23(2):177-89. PubMed ID: 18515444
[TBL] [Abstract][Full Text] [Related]
54. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat.
Shirazi-Southall S; Rodriguez DE; Nomikos GG
Neuropsychopharmacology; 2002 May; 26(5):583-94. PubMed ID: 11927183
[TBL] [Abstract][Full Text] [Related]
55. Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino)tetralin and its enantiomers.
Christoffersen CL; Meltzer LT
Neuropsychopharmacology; 1998 May; 18(5):399-402. PubMed ID: 9536454
[TBL] [Abstract][Full Text] [Related]
56. Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study.
Østbye T; Curtis LH; Masselink LE; Hutchison S; Wright A; Dans PE; Schulman KA; Krishnan RR
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):407-15. PubMed ID: 15372671
[TBL] [Abstract][Full Text] [Related]
57. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia.
Langlois X; Megens A; Lavreysen H; Atack J; Cik M; te Riele P; Peeters L; Wouters R; Vermeire J; Hendrickx H; Macdonald G; De Bruyn M
J Pharmacol Exp Ther; 2012 Jul; 342(1):91-105. PubMed ID: 22490380
[TBL] [Abstract][Full Text] [Related]
58. WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics.
Grauer SM; Graf R; Navarra R; Sung A; Logue SF; Stack G; Huselton C; Liu Z; Comery TA; Marquis KL; Rosenzweig-Lipson S
Psychopharmacology (Berl); 2009 May; 204(1):37-48. PubMed ID: 19107466
[TBL] [Abstract][Full Text] [Related]
59. Similarities and differences among antipsychotics.
Tamminga CA
J Clin Psychiatry; 2003; 64 Suppl 17():7-10. PubMed ID: 14680420
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies.
Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
Neuropsychopharmacology; 2007 Jul; 32(7):1540-9. PubMed ID: 17164815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
